| WB | 1/500 - 1/2000 | Human,Monkey |
| IF | 咨询技术 | Human,Monkey |
| IHC | 1/200 - 1/1000 | Human,Monkey |
| ICC | 技术咨询 | Human,Monkey |
| FCM | 1/200 - 1/400 | Human,Monkey |
| Elisa | 1/10000 | Human,Monkey |
| Aliases | SMA; SMN; SMA1; SMA2; SMA3; SMA4; SMA@; SMN2; SMNT; BCD541; T-BCD541 |
| Entrez GeneID | 6606 |
| clone | 2F1 |
| WB Predicted band size | 39kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Monkey |
| Immunogen | Purified recombinant fragment of human SMN1 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4条关于SMN1抗体的假设参考文献示例(内容为虚构，仅供格式参考)：
1. **文献名称**：《抗SMN1单克隆抗体的制备及其在脊髓性肌萎缩症诊断中的应用》
**作者**：李明等
**摘要**：研究通过重组SMN1蛋白免疫小鼠制备高特异性单克隆抗体，并建立ELISA检测方法，证实该抗体可有效区分SMN1与SMN2蛋白表达差异，为SMA的早期筛查提供工具。
2. **文献名称**：《SMN1抗体在神经细胞模型中的功能验证》
**作者**：Chen Y, Smith J.
**摘要**：利用CRISPR/Cas9敲低SMN1的神经元模型，验证商业化SMN1抗体的特异性，发现其能精准定位SMN1蛋白亚细胞分布，支持其在神经退行机制研究中的可靠性。
3. **文献名称**：《基于SMN1抗体的基因治疗疗效评估新策略》
**作者**：Wang X et al.
**摘要**：开发基于SMN1抗体的免疫组化定量方法，用于评估腺相关病毒(AAV)介导的基因疗法对SMA小鼠模型的治疗效果，证明治疗后运动神经元SMN1表达显著恢复。
4. **文献名称**：《SMN1/2抗体交叉反应性分析与临床意义》
**作者**：Garcia R, Tanaka K.
**摘要**：系统性比较多种市售SMN1抗体的交叉反应性，发现部分抗体对SMN2存在非特异性结合，提示临床检测中需严格验证抗体特异性以避免假阳性结果。
(注：以上文献及作者名为虚构示例，实际研究中请通过PubMed或Google Scholar检索真实文献。)
The survival motor neuron 1 (SMN1) gene encodes the SMN protein, essential for the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs) and motor neuron survival. Loss of SMN1 function due to mutations or deletions causes spinal muscular atrophy (SMA), a leading genetic cause of infant mortality. SMN1 antibodies are critical tools for studying SMN protein expression, localization, and function in both research and diagnostic contexts. These antibodies are typically developed against specific epitopes of the SMN protein, enabling detection via techniques like Western blot, immunohistochemistry, or immunofluorescence.
Since SMN1 and its nearly identical paralog SMN2 differ by a single nucleotide (affecting protein splicing efficiency), antibodies must distinguish between full-length SMN (primarily from SMN1) and truncated isoforms (from SMN2) to assess functional protein levels. High-quality SMN1 antibodies aid in understanding SMA pathogenesis, monitoring therapeutic responses (e.g., antisense oligonucleotides or gene therapy), and validating SMN-upregulating drugs. Challenges include ensuring specificity due to the high homology between SMN1 and SMN2-derived proteins. Recent advancements in antibody engineering have improved selectivity, supporting precision in basic research and clinical applications aimed at mitigating SMA progression.
×
